Zenas Biopharma Inc
ZBIO
查看详细走势图
42.490USD
-0.680-1.58%
收盘 12/26, 16:00（美东）报价延迟15分钟
1.79B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.58%
5天
+17.54%
1月
+4.84%
6月
+318.62%
今年开始到现在
+418.80%
1年
+322.79%
查看详细走势图
TradingKey Zenas Biopharma Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Zenas Biopharma Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名33/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价45.00。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Zenas Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
8
位分析师
强力买入
评级
45.000
目标均价
+14.31%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Zenas Biopharma Inc亮点
亮点风险
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
业绩增长期
公司处于发展阶段，最新年度总收入5.00M美元
利润高增长
公司净利润处于行业前列，最新年度总收入5.00M美元
估值低估
公司最新PE估值-3.35，处于3年历史低位
机构加仓
最新机构持股33.16M股，环比增加5.85%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值332.00
Zenas Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Zenas Biopharma Inc简介
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
公司代码ZBIO
公司Zenas Biopharma Inc
CEOMoulder (Leon O)
网址https://zenasbio.com/
常见问题
Zenas Biopharma Inc(ZBIO)的当前股价是多少？
Zenas Biopharma Inc(ZBIO)的当前股价是 42.490。
Zenas Biopharma Inc的股票代码是什么？
Zenas Biopharma Inc的股票代码是ZBIO。
Zenas Biopharma Inc股票的52周最高点是多少？
Zenas Biopharma Inc股票的52周最高点是44.600。
Zenas Biopharma Inc股票的52周最低点是多少？
Zenas Biopharma Inc股票的52周最低点是5.830。
Zenas Biopharma Inc的市值是多少？
Zenas Biopharma Inc的市值是1.79B。
Zenas Biopharma Inc的净利润是多少？
Zenas Biopharma Inc的净利润为-156.99M。
现在Zenas Biopharma Inc(ZBIO)的股票是买入、持有还是卖出？
根据分析师评级，Zenas Biopharma Inc(ZBIO)的总体评级为--，目标价格为45.000。
Zenas Biopharma Inc(ZBIO)股票的每股收益（EPS TTM）是多少
Zenas Biopharma Inc(ZBIO)股票的每股收益（EPS TTM）是-12.669。
相关品种
